$DFCO
DALRADA FINANCIAL CORP Stock $dfco

$dfco Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000168316823003389 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$10.75M	$9.475M	$5.592M
YoY Change	196.58%	69.43%	252.08%
Cost Of Revenue	$8.755M	$6.613M	$1.774M
YoY Change	134.91%	272.83%	107.49%
Gross Profit	$1.998M	$2.862M	$3.819M
YoY Change	-2076.54%	-25.05%	420.56%
Gross Profit Margin	18.58%	30.21%	68.28%
Selling, General & Admin	$10.85M	$6.501M	$6.293M
YoY Change	174.36%	3.3%	115.69%
% of Gross Profit	542.91%	227.16%	164.81%
Research & Development	$120.0K	$0.00	$0.00
YoY Change	-81.69%		-100.0%
% of Gross Profit	6.0%	0.0%	0.0%
Depreciation & Amortization	$177.4K	$94.33K	$62.65K
YoY Change	6.78%	50.57%	849.24%
% of Gross Profit	8.88%	3.3%	1.64%
Operating Expenses	$11.15M	$6.501M	$6.458M
YoY Change	134.21%	0.67%	112.2%
Operating Profit	-$9.149M	-$3.639M	-$2.640M
YoY Change	88.23%	37.87%	14.27%
Interest Expense	-$249.3K	$314.3K	-$349.5K
YoY Change	-62.28%	-189.94%	118.43%
% of Operating Profit
Other Income/Expense, Net	$902.2K	-$406.6K	-$3.970K
YoY Change	166.96%	10141.26%	-963.04%
Pretax Income	-$8.930M	-$4.046M	-$2.993M
YoY Change	65.31%	35.17%	21.2%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.236M	-$4.026M	-$3.423M
YoY Change	63.93%	17.6%	38.89%
Net Earnings / Revenue	-76.59%	-42.49%	-61.21%
Basic Earnings Per Share		-$0.05	-$0.05
Diluted Earnings Per Share	-$0.09	-$0.05	-$48.74K
COMMON SHARES
Basic Shares Outstanding	88.70M shares	85.66M shares	70.24M shares
Diluted Shares Outstanding		85.73M shares	70.24M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$812.8K	$1.289M	$547.3K
YoY Change	-8.86%	135.51%	106.36%
Cash & Equivalents	$812.8K	$1.289M	$547.3K
Short-Term Investments
Other Short-Term Assets	$1.343M	$337.8K	$161.6K
YoY Change	212.39%	109.01%	-29.93%
Inventory	$2.079M	$2.321M	$1.157M
Prepaid Expenses
Receivables	$4.453M	$8.218M	$7.724M
Other Receivables	$376.6K	$534.8K	$171.3K
Total Short-Term Assets	$9.817M	$12.83M	$9.761M
YoY Change	2.65%	31.43%	311.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.476M	$1.404M	$2.139M
YoY Change	37.13%	-34.38%	64.12%
Goodwill	$3.803M	$4.253M
YoY Change	-10.59%
Intangibles	$3.858M	$3.920M
YoY Change	9.45%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$15.35M	$15.90M	$3.752M
YoY Change	19.39%	323.84%	35.76%
TOTAL ASSETS
Total Short-Term Assets	$9.817M	$12.83M	$9.761M
Total Long-Term Assets	$15.35M	$15.90M	$3.752M
Total Assets	$25.17M	$28.73M	$13.51M
YoY Change	12.25%	112.62%	163.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.179M	$4.598M	$1.033M
YoY Change	122.09%	344.89%	161.94%
Accrued Expenses	$1.084M	$1.717M	$3.903M
YoY Change	-39.76%	-56.0%	-66.11%
Deferred Revenue	$1.337M	$1.973M
YoY Change	85.49%
Short-Term Debt	$251.6K	$16.73M	$6.735M
YoY Change	-97.66%	148.34%	-30.72%
Long-Term Debt Due	$439.6K	$1.035M
YoY Change	-34.3%
Total Short-Term Liabilities	$10.02M	$28.94M	$13.57M
YoY Change	-50.93%	113.22%	-39.19%
LONG-TERM LIABILITIES
Long-Term Debt	$2.709M	$13.73M	$10.02M
YoY Change	-73.28%	37.0%	3240.93%
Other Long-Term Liabilities	$8.188M	$8.767M	$836.2K
YoY Change	20.05%	948.43%	15.58%
Total Long-Term Liabilities	$10.90M	$22.49M	$10.86M
YoY Change	-35.75%	107.21%	960.78%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.02M	$28.94M	$13.57M
Total Long-Term Liabilities	$10.90M	$22.49M	$10.86M
Total Liabilities	$20.92M	$51.44M	$25.66M
YoY Change	-44.04%	100.47%	9.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.7M	-$133.5M
YoY Change	16.71%
Common Stock	$443.5K	$431.2K
YoY Change	22.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.109M	-$23.54M	-$12.14M
YoY Change
Total Liabilities & Shareholders Equity	$25.17M	$28.73M	$13.51M
YoY Change	12.25%	112.62%	163.12%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$8.236M	-$4.026M	-$3.423M
YoY Change	63.93%	17.6%	38.89%
Depreciation, Depletion And Amortization	$177.4K	$94.33K	$62.65K
YoY Change	6.78%	50.57%	849.24%
Cash From Operating Activities	$5.462M	-$5.163M	-$2.837M
YoY Change	-296.23%	81.97%	70.69%
INVESTING ACTIVITIES
Capital Expenditures	$205.4K	-$32.87K	-$309.9K
YoY Change	-187.55%	-89.39%	747.54%
Acquisitions
YoY Change
Other Investing Activities	$20.36K	$9.110K
YoY Change	-93.39%
Cash From Investing Activities	-$185.1K	$41.98K	-$309.9K
YoY Change	-351.64%	-113.55%	-1023.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-5.723M	4.873M	3.519M
YoY Change	-287.5%	38.5%	104.56%
NET CHANGE
Cash From Operating Activities	5.462M	-5.163M	-2.837M
Cash From Investing Activities	-185.1K	41.98K	-309.9K
Cash From Financing Activities	-5.723M	4.873M	3.519M
Net Change In Cash	-446.5K	-247.9K	371.5K
YoY Change	-230.38%	-166.73%	306.17%
FREE CASH FLOW
Cash From Operating Activities	$5.462M	-$5.163M	-$2.837M
Capital Expenditures	$205.4K	-$32.87K	-$309.9K
Free Cash Flow	$5.256M	-$5.130M	-$2.528M
YoY Change	-306.23%	102.98%	55.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000725394
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2021Q4	DFCO	Issuance Of Preferred Stock IssuanceOfPreferredStock		usd
CY2021Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2021Q4	DFCO	Reversal Of Shares Previously Issued To Directors ReversalOfSharesPreviouslyIssuedToDirectors		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions		usd
CY2023Q1	DFCO	Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-12641
	dei	Entity Registrant Name EntityRegistrantName	DALRADA FINANCIAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3713274
	dei	Entity Address Address Line1 EntityAddressAddressLine1	600 La Terraza Blvd.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Escondido
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92025
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	283-1253
	dei	Security12b Title Security12bTitle	Common Stock, $0.005 par value per share
	dei	Trading Symbol TradingSymbol	DFCO
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	88699139	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1288916	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	0	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8218196	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6406555	usd
CY2023Q1	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	127951	usd
CY2022Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	41603	usd
CY2023Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	534761	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	288655	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2321316	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	337828	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	430070	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	12828968	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	9563566	usd
CY2023Q1	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41716	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2023Q1	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1182893	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties LongtermReceivablesRelatedParties	1209103	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1403890	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2023Q1	us-gaap	Goodwill Goodwill	4253424	usd
CY2022Q2	us-gaap	Goodwill Goodwill	4253424	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3920496	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3524888	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2713785	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1665436	usd
CY2023Q1	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	2385014	usd
CY2022Q2	DFCO	Right Of Use Asset Net Related Party RightOfUseAssetNetRelatedParty	1087256	usd
CY2023Q1	us-gaap	Assets Assets	28730186	usd
CY2022Q2	us-gaap	Assets Assets	22422480	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4597505	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2331919	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1717484	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1799404	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	0	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2055736	usd
CY2023Q1	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	1792753	usd
CY2022Q2	DFCO	Accounts Payable And Accrued Liabilities Related Parties Current AccountsPayableAndAccruedLiabilitiesRelatedPartiesCurrent	1270133	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1972516	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	720923	usd
CY2023Q1	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1035189	usd
CY2022Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	669028	usd
CY2023Q1	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	16726676	usd
CY2022Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	9269377	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1495528	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	587527	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	435647	usd
CY2023Q1	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	511772	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Current RightOfUseLiabilityRelatedPartyCurrent	369050	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	28941422	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	20416745	usd
CY2023Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	73205	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	120534	usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	479001	usd
CY2023Q1	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	13174894	usd
CY2022Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	9538685	usd
CY2023Q1	DFCO	Contingent Consideration ContingentConsideration	4767333	usd
CY2022Q2	DFCO	Contingent Consideration ContingentConsideration	4870800	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2126258	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231691	usd
CY2023Q1	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	1873242	usd
CY2022Q2	DFCO	Right Of Use Liability Related Party Non Current RightOfUseLiabilityRelatedPartyNonCurrent	718206	usd
CY2023Q1	us-gaap	Liabilities Liabilities	51435355	usd
CY2022Q2	us-gaap	Liabilities Liabilities	37375662	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86240807	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86240807	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72174620	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72174620	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	431187	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	360855	usd
CY2023Q1	DFCO	Common Stock To Be Issued CommonStockToBeIssued	317925	usd
CY2022Q2	DFCO	Common Stock To Be Issued CommonStockToBeIssued	1066925	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109222356	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104627032	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133492861	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121436490	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21177	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50673	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-23542420	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-15432201	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	837251	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	479019	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22705169	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28730186	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22422480	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9290805	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5572826	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18066932	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15530319	usd
CY2023Q1	DFCO	Revenues Related Party RevenuesRelatedParty	183888	usd
CY2022Q1	DFCO	Revenues Related Party RevenuesRelatedParty	19324	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	918648	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	111448	usd
CY2023Q1	us-gaap	Revenues Revenues	9474693	usd
CY2022Q1	us-gaap	Revenues Revenues	5592150	usd
	us-gaap	Revenues Revenues	18985580	usd
	us-gaap	Revenues Revenues	15641767	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6612680	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1773630	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11924140	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5034308	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2862013	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	3818520	usd
	us-gaap	Gross Profit GrossProfit	7061440	usd
	us-gaap	Gross Profit GrossProfit	10607459	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	815454	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	362532	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2184692	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2145626	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6501233	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6458163	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18438927	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	16000902	usd
CY2023Q1	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	0	usd
CY2022Q1	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	0	usd
	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	0	usd
	DFCO	Research And Development Expenses ResearchAndDevelopmentExpenses	1596	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	6501233	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	6458163	usd
	us-gaap	Operating Expenses OperatingExpenses	18438927	usd
	us-gaap	Operating Expenses OperatingExpenses	16002498	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3639220	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2639643	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11377487	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5395039	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	314319	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	338677	usd
	us-gaap	Interest Expense InterestExpense	2207049	usd
	us-gaap	Interest Expense InterestExpense	597551	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	18830	usd
CY2022Q1	us-gaap	Interest Income Operating InterestIncomeOperating	4232	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	60725	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	5280	usd
CY2023Q1	us-gaap	Other Income OtherIncome	-72933	usd
CY2022Q1	us-gaap	Other Income OtherIncome	-3974	usd
	us-gaap	Other Income OtherIncome	-179555	usd
	us-gaap	Other Income OtherIncome	9270	usd
CY2023Q1	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
CY2022Q1	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	0	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-38156	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-15018	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-85751	usd
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-59351	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-406578	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-353437	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-320652	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-642352	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4045798	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2993080	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11698139	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6037391	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-137	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4990	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	29496	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	34679	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4045935	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2998070	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11668643	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6002712	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-20234	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	430147	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	358232	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3036854	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4025564	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3423227	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12056371	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9074245	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85728770	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70235384	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82356784	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72718261	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85728770	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70235384	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82356784	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	72718261	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13407388	usd
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	6532206	usd
CY2021Q3	DFCO	Joint Venture JointVenture	169745	usd
CY2021Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	14826	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	677507	usd
CY2021Q3	DFCO	Profit Loss1 ProfitLoss1	-976673	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39344	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6980085	usd
CY2021Q4	DFCO	Joint Venture JointVenture	-1874244	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1105587	usd
CY2021Q4	DFCO	Profit Loss1 ProfitLoss1	-2067638	usd
CY2021Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	325	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9816053	usd
CY2022Q1	DFCO	Common Stock Issued In Connection With Convertible Note CommonStockIssuedInConnectionWithConvertibleNote	1542695	usd
CY2022Q1	DFCO	Joint Venture JointVenture	-7900	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	362532	usd
CY2022Q1	DFCO	Profit Loss1 ProfitLoss1	-2993080	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4990	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10916796	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-14953182	usd
CY2022Q3	DFCO	Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium	1111397	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	172350	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	467517	usd
CY2022Q3	DFCO	Profit Loss1 ProfitLoss1	-3170176	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	63762	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16308332	usd
CY2022Q4	DFCO	Common Stock Issued For Conversion Of Convertibles Notes Accrued Interest And Premium CommonStockIssuedForConversionOfConvertiblesNotesAccruedInterestAndPremium	336091	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	75459	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	901721	usd
CY2022Q4	DFCO	Profit Loss1 ProfitLoss1	-4482165	usd
CY2022Q4	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-34129	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-19511355	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	36667	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	815454	usd
CY2023Q1	DFCO	Profit Loss1 ProfitLoss1	-4045798	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-137	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-22705169	usd
	us-gaap	Profit Loss ProfitLoss	-11698139	usd
	us-gaap	Profit Loss ProfitLoss	-6037391	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	530177	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	156897	usd
	DFCO	Share Based Compensation1 ShareBasedCompensation1	2184692	usd
	DFCO	Share Based Compensation1 ShareBasedCompensation1	2145626	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	146475	usd
	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	181009	usd
	DFCO	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	0	usd
	DFCO	Bad Debt Expense BadDebtExpense	640484	usd
	DFCO	Bad Debt Expense BadDebtExpense	0	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	2090978	usd
	DFCO	Gain On Expiration Of Accrued Tax Liability GainOnExpirationOfAccruedTaxLiability	-0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2787677	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7388104	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	218817	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	103932	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	696695	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	314573	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-128542	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-123392	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-26889	usd
	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2241421	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	123063	usd
	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	-47329	usd
	DFCO	Increase Decrease In Longterm Payables IncreaseDecreaseInLongtermPayables	0	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	522620	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	1967786	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-217742	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1100808	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	35242	usd
	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	72558	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1191593	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	441075	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10074709	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7566320	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	511515	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	441521	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	446923	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	206068	usd
	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	80087	usd
	DFCO	Acquisition Of Business Net Of Cash AcquisitionOfBusinessNetOfCash	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-878351	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-647589	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	11845764	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	7602059	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2932857	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	752256	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	-0	usd
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	-0	usd
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	1882144	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	346910	usd
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-21717	usd
	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary	-0	usd
	DFCO	Repurchase Of Common Shares From Subsidiary RepurchaseOfCommonSharesFromSubsidiary	14826	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11440418	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8616229	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	487358	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	402320	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29496	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34679	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	772062	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110285	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1288916	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	547284	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	0	usd
	DFCO	Conversion Of Related Party Notes And Interest Into Preferred Stock ConversionOfRelatedPartyNotesAndInterestIntoPreferredStock	6532206	usd
	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	0	usd
	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	0	usd
	DFCO	Issuance Of Shares To Joint Venture Partner IssuanceOfSharesToJointVenturePartner	58560	usd
	DFCO	Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties	0	usd
	DFCO	Conversion Of Accounts Payablerelated Parties To Note Payablerelated Parties ConversionOfAccountsPayablerelatedPartiesToNotePayablerelatedParties	181744	usd
	DFCO	Common Stock And Warrants Issued In Connection With Convertible Note CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote	0	usd
	DFCO	Common Stock And Warrants Issued In Connection With Convertible Note CommonStockAndWarrantsIssuedInConnectionWithConvertibleNote	1542695	usd
	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	2327489	usd
	DFCO	Conversion Of Convertible Note Payable Accrued Interest And Premium Into Common Stock ConversionOfConvertibleNotePayableAccruedInterestAndPremiumIntoCommonStock	0	usd
	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	1447488	usd
	DFCO	Increase In Right Of Use Asset And Liability IncreaseInRightOfUseAssetAndLiability	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zEIxHcAQ2Efb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zcpcAZfwPTj7">Organization and Nature of Operations</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Financial Corporation, (“Dalrada”), was incorporated in September 1982 under the laws of the State of California. It was reincorporated in May 1983 under the laws of the State of Delaware and reincorporated again on May 5, 2020, under the laws of the state of Wyoming. Dalrada Financial Corporation trades under the symbol, OTCQB: DFCO.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since Dalrada’s inception, the Company has grown its footprint to include the unique business divisions: <b>Genefic</b>, <b>Dalrada Energy Services</b>, <b>Dalrada Precision Manufacturing</b>, and <b>Dalrada Technologies</b>. Dalrada’s global solutions directly address climate change, gaps in the health care industry, and technology needs that facilitate a new era of human behavior and interaction and ensure a bright future for the world around us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Genefic</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Genefic, formerly named Dalrada Health, delivers advanced health care solutions with dedicated products, services, and systems. From virus and disease screening capabilities to pharmaceutical goods and holistic wellness clinics, this specialized division is committed to developing key health products, lifesaving medications and building comprehensive systems to increase capability, strive to keep people healthy with the goals of improving their quality of life and increasing their longevity– on a global level.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Empower Genomics (“Empower”)</b>- Empower is Dalrada’s wholly owned diagnostic laboratory which processes molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus. Empower has built up and maintained the testing capacity to handle surges in COVID-19 testing demands. Empower also offers genetic testing capabilities including Pharmacogenomics, Nutraceutical, Nutrition/Diet DNA and Exercise/Fitness DNA tests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pala Diagnostics (“Pala”)</b>- Pala is a joint venture diagnostic laboratory which processes both molecular diagnostic and antibody tests to support the diagnosis of COVID-19 and the detection of immune response to the virus.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Solas Corp. (“Solas”)</b>- Solas manages and oversees wellness clinics throughout Southern California including the Sòlas Rejuvenation + Wellness clinics (“Sòlas”). Through advanced medical techniques and modern technology, Sòlas delivers a clinical experience that helps men and woman live their best life, whether it’s through simple cosmetic procedures, pain-reducing practices, or anti-aging therapies. Through its three locations, Sòlas prides itself on its dedicated service-focused, health-first approach. Its wellness & rejuvenation clinics deliver with a focus on regenerative therapies, IV and injection services, cosmetic enhancements amongst a myriad of additional health centric services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>International Health Group (“IHG”)</b>- IHG provides highly trained nursing and medical assistants for hospitals and home health facilities since 2006. IHG Medical Assistant programs include Certified Nursing Assistant (“CNA") and Home Health Aide (“HHA”) training and the fast-track 22-Day CNA Certification Program at its state-approved testing facility.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Pacific Stem Cells (“PSC”)</b>- PSC markets and sells traditional biologics and human cells, tissues, and cellular and tissue-based products (HCT/Ps).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Watson Rx Solutions (“Watson”)</b>- In June 2022, Dalrada Life Sciences acquired Watson, an Alabama-based pharmacy with more than 30 years of experience in the retail medical and pharmaceutical industries. Watson helps manage disease states through education and prescription management while offering generic as well as specialty medications. Watson maintains pharmacy licenses in all 50 States including Washington D.C.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>GlanHealth (“GlanHealth”)</b>- Dalrada Health Products launched GlanHealth in 2020 to distribute alcohol-free hand sanitizers, surface cleaners, laundry aides, antimicrobial solutions, electrostatic sprayers, face masks, gloves, kits, and delivery equipment such as dispensers, stands, and ease of use packaging for the end consumer. GlanHealth leverages an extensive supply chain of producers, resellers, distributors, vendors, and formulators for the development, sale, and marketing of its products and services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Energy Services</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Energy Services (‘DES’) employs next-generation technology that enhances clean energy efforts while reducing the world’s carbon footprint. Through innovative products and commercial services, DES facilitates energy transition for universities, businesses, government buildings, and more.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Energy Services (“DES”)</b>- DES provides end-to-end comprehensive energy service solutions in a robust commercial capacity, DES helps organizations meet environmental, social, and governance (“ESG”) goals and standards while mitigating negative environmental impacts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Bothof Brothers Construction (“Bothof”)</b>- Bothof is a licensed general contractor which provides a wide range of development, construction and design capabilities and expertise throughout the United States. Through Bothof’s extensive experience in construction and contracting, the DES division is able to provide a myriad of additional services to its private and public works customers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Precision Manufacturing</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Precision Manufacturing creates total manufacturing solutions that start with the design and development of high-quality machine parts and components, and end with an efficient global supply chain. This specialized business division can meet today’s high demands and solves industry challenges. Dalrada Precision Manufacturing is confident that it redefines the critical quality of the world’s top components and responds with in-house research, design, engineering, and distribution through a highly reliable global supply chain and improved time-to-market capabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Precision Parts (“Precision”)</b>- Precision extends the client its engineering and operations team by helping devise unique manufacturing solutions tailored to their products. Dalrada Precision can enter at any stage of the product lifecycle from concept and design to mass production and logistics.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Likido Ltd. (“Likido”)</b>- Likido is an international engineering company developing advanced solutions for the harvesting and recycling of energy. Using its novel, heat pump systems (patent pending), Likido is working to revolutionize the renewable energy sector with the provision of innovative modular process technologies to maximize the capture and reuse of thermal energy for integrated heating and cooling applications. With uses across industrial, commercial and residential sectors, Likido provides cost savings and the minimized carbon emissions across global supply chains. Likido's technologies enable the effective recovery and recycling of process energy, mitigating against climate change and expected enhancement of quality of life through the provision of low-carbon heating and cooling systems. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Ignite I.T. (“Ignite”)</b>- Ignite is a manufacturer and seller of eco-friendly deep cleaners, parts washers and degreasers that are specially formulated to lift hydrocarbon-based dirt and grease from virtually all surfaces with minimal effort. Ignite products are non-flammable, non-corrosive, non-toxic, butyl-free, water-based, and leave a light citrus scent. Ignite is developed for all surfaces suitable for water and meet or exceed the most stringent industry-testing specifications. Ignites products are effective and available solutions to the increased demand for protecting employees from hazardous chemicals currently used and highlighted in recent federal and state regulations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Deposition Technologies (“DepTec”)</b>- Dalrada Precision Manufacturing acquired DepTec in April 2022. DepTec designs, develops, manufactures, and services chemical vapor and physical vapor deposition systems for the microchip and semiconductor industries.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">DepTec has built a multitude of precision OEM parts for PVD (Physical vapor deposition) and refurbished systems which allow clients the option of purchasing the same model of system they’ve been using for decades – but with upgrades and improved efficiencies. DepTec also has its own PVD and CVD (Chemical Vapor Deposition) systems, EVOS-PVD and EVOS -CVD, which deposits metals and non-metals for microchips used in almost every standard and specialized microdevices made today and in the future. These systems can produce a superior film layer utilized in rugged high-stress environment designs and expect to meet the increased US market demand driven by the CHIPS and Science Act of 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Dalrada Technology Limited (“DTL”)- </b>Dalrada Precision Manufacturing Inc. entered into an Ownership Purchase Agreement to purchase all of the membership interests in Dalrada Technology Limited on March 1, 2023. DTL is a holding company for all European based Dalrada Precision entities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Dalrada Technologies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dalrada Technologies has worked with some of the world’s most recognizable companies, providing digital engineering for cutting-edge software systems and offering a host of robust digital services. This business division connects the world with integrated technology and innovative solutions, delivering advanced capabilities and error-free results. Dalrada Technologies creates digital products with expert computer information technology and software engineering services for a variety of technical industries and clients in both B2B and B2C environments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><b>Prakat (“Prakat”)</b>- Prakat is an ISO 9001-certified company that provides end-to-end technology services across various industries, improving the value chain. The Company specializes in test engineering, accessibility engineering, product engineering, application modernization, billing and revenue management, CRM, and block chain. Prakat provides global customers with software and technology solutions specializing in Test Engineering, Accessibility Engineering, Product Engineering and Application Modernization.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Liquidity and Going Concern</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These condensed consolidated financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of March 31, 2023, the Company has an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230331_zepQgQS1QoVk" title="Accumulated deficit">133,492,861</span>. The Company closed a convertible debenture funding on February 4, 2022 for a total principal amount of $<span id="xdx_90B_eus-gaap--ProceedsFromConvertibleDebt_pp0p0_c20220203__20220204_zoGmVQEJvQpe" title="Principal amount">3,000,000</span>. The continuation of the Company as a going concern is dependent upon the continued financial support from related parties, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133492861	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_ztXTqo4MZSuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_861_zmSt4XU5deKl">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the valuation of inventory, valuation of accrued payroll tax liabilities, valuation of acquired assets and liabilities, variables used in the computation of share-based compensation, and deferred income tax asset valuation allowances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zyMIun2GNdEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zfbYKI4HNaA9">Concentrations of Credit Risk</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When estimating its allowance for credit losses related to revenues from Covid Testing, the Company differentiates its receivables based on the following customer types: healthcare insurers, government payers, and cash payers. Additionally, the Company applies assumptions and judgments for assessing collectability and determining net revenues and accounts receivable from its customers. Historical collection factors we considered for assessing collectability and determining net revenues and accounts receivable from our customers include the period that the receivables have been outstanding, history of payment amounts, status of collections due, and applicable statutes of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended March 31, 2023, healthcare insurers and government payers accounted for over <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220701__20230331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--HealthcareInsurersAndGovernmentPayersMember_zgwOzd9AH411" title="Concentrations of credit risk">29</span>% of total revenues or $<span id="xdx_90B_eus-gaap--Revenues_pp0p0_c20220701__20230331__srt--ProductOrServiceAxis__custom--HealthcareInsurersMember_zcaBAQ3DB1Kb" title="Revenues">5,567,245</span>. The accounts receivable related to both healthcare insurers and government payers was $<span id="xdx_907_eus-gaap--AccountsReceivableNet_iI_pp0p0_c20230331__srt--ProductOrServiceAxis__custom--HealthcareInsurersAndGovernmentPayersMember_z8vGFbMR8hg5" title="Accounts Receivable, after Allowance for Credit Loss">3,863,560</span> as of March 31, 2023.</p>
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	223062	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	119791	usd
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	218308	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2022Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9474693	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5592150	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18985580	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15641767	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	8218196	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	6406555	usd
CY2023Q1	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	127951	usd
CY2022Q2	DFCO	Accounts Receivable Net Related Parties Current AccountsReceivableNetRelatedPartiesCurrent	41603	usd
CY2023Q1	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	41716	usd
CY2022Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	42395	usd
CY2023Q1	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1182893	usd
CY2022Q2	DFCO	Longterm Receivables Related Parties Current LongtermReceivablesRelatedPartiesCurrent	1209103	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	1972516	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	720923	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	362532	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6612680	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1773630	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11924140	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5034308	usd
	us-gaap	Advertising Expense AdvertisingExpense	275846	usd
	us-gaap	Advertising Expense AdvertisingExpense	366551	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	74846	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	138551	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	815454	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2184692	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2145626	usd
	DFCO	Change In Fair Value Of Contingent Consideration1 ChangeInFairValueOfContingentConsideration1	103467	usd
CY2023Q1	DFCO	Contingent Consideration ContingentConsideration	4767333	usd
CY2021Q3	DFCO	Contribution Of Property And Equipment Into Joint Venture ContributionOfPropertyAndEquipmentIntoJointVenture	111185	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	30000	usd
CY2022Q4	DFCO	Warrants Issued WarrantsIssued	3000000	shares
CY2022Q4	DFCO	Strike Price StrikePrice	0.15
CY2022Q4	DFCO	Cashless Warrants Vest CashlessWarrantsVest	450000	usd
CY2022Q4	DFCO	Cashless Warrants CashlessWarrants	6000000	usd
CY2022Q4	DFCO	Warrant Consideration WarrantConsideration	3482550	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	70979	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	27289	usd
CY2022Q4	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Right Of Use Asset Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightOfUseAssetNet	18618	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	17179	usd
CY2022Q4	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Name BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName	6776	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	24165	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	18807	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Deferred Revenue BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue	60000	usd
CY2022Q4	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Right Of Use Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesRightOfUseLiability	18618	usd
CY2022Q4	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Notes Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesNotesPayable	19251	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	0	usd
CY2023Q1	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Rate NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationRate	1	pure
CY2023Q1	DFCO	Warrants Issued WarrantsIssued	1000000	shares
CY2023Q1	DFCO	Strike Price StrikePrice	0.10
CY2023Q1	DFCO	Warrant Consideration WarrantConsideration	68975	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	9108	usd
CY2023Q1	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deposits BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeposits	13536	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	24666	usd
CY2023Q1	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Furniture And Fixtures BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFurnitureAndFixtures	64533	usd
CY2023Q1	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Trade Name BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName	206336	usd
CY2023Q1	DFCO	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Loan Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLoanPayable	249204	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	68975	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1193509	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	399706	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1127807	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1224915	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2321316	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1474850	usd
CY2022Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	740147	usd
CY2023Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	303922	usd
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	314642	usd
CY2023Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	429027	usd
CY2022Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	518017	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2207799	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1572806	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	803909	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	496394	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1403890	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	265749	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	103566	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	94331	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9313	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3670665	usd
	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	654554	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	4325219	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	145777	usd
	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	258946	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	404723	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3920496	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	693385	usd
CY2022	DFCO	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	2977280	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3670665	usd
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28891	usd
CY2022	DFCO	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	116886	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	145777	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3524888	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	264428	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	155570	usd
CY2023Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	87334	usd
CY2022Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	120131	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	0	usd
CY2022Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2055736	usd
	DFCO	Accrued Interest Rate AccruedInterestRate	Accrued interest is compounded daily at an estimated effective interest rate of 7.33%.
CY2023Q1	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	29901570	usd
CY2023Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	968011	usd
CY2022Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	18808062	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	362855	usd
CY2023Q1	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	16726676	usd
CY2023Q1	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	13174894	usd
CY2023Q1	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	29901570	usd
CY2022Q2	DFCO	Notes Payable Related Parties Current NotesPayableRelatedPartiesCurrent	9269377	usd
CY2022Q2	DFCO	Notes Payable Related Parties Noncurrent1 NotesPayableRelatedPartiesNoncurrent1	9538685	usd
CY2022Q2	DFCO	Notes Payable Related Parties NotesPayableRelatedParties	18808062	usd
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	3320	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid	466460	usd
	us-gaap	Line Of Credit Facility Interest Rate Description LineOfCreditFacilityInterestRateDescription	interest rate of Prime + 1%
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2021-05-05
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	600000	usd
	DFCO	Redemption Premium In Cash RedemptionPremiumInCash	120000	usd
	DFCO	Debenture In Cash DebentureInCash	600000	usd
CY2023Q1	DFCO	Revenues Related Party RevenuesRelatedParty	183888	usd
CY2022Q1	DFCO	Revenues Related Party RevenuesRelatedParty	19324	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	918648	usd
	DFCO	Revenues Related Party RevenuesRelatedParty	111448	usd
	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	Each share of Series G Convertible Preferred share converts into 2,177 shares of common stock (equivalent to converting the related equity dollars into common shares at $0.30 per share).
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.59
CY2022Q1	DFCO	Fair Value Of Options Granted FairValueOfOptionsGranted	1338644	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.45
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	250000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.15
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11025004	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.45
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12025004	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	5200000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.27
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17225004	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.40
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12882260	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.43
	us-gaap	Share Based Compensation ShareBasedCompensation	2184692	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2145626	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3521116	usd
CY2023Q1	us-gaap	Revenues Revenues	9474693	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3639220	usd
CY2022Q1	us-gaap	Revenues Revenues	5592150	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2639643	usd
	us-gaap	Revenues Revenues	18985580	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11377487	usd
	us-gaap	Revenues Revenues	15641767	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5395039	usd
	us-gaap	Revenues Revenues	18985580	usd
	us-gaap	Revenues Revenues	15641767	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2321316	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1624621	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1403890	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1076412	usd
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2405540	usd
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2405540	usd
CY2020Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.030	pure
CY2020Q2	DFCO	Imputed Interest ImputedInterest	192521	usd
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	140569	usd
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	140569	usd
CY2020Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.030	pure
CY2020Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.030	pure
CY2023Q1	us-gaap	Notes Payable NotesPayable	509731	usd

Files In Submission

Name	View Source	Status
dfco-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001683168-23-003389-index-headers.html	Edgar Link	pending
0001683168-23-003389-index.html	Edgar Link	pending
0001683168-23-003389.txt	Edgar Link	pending
0001683168-23-003389-xbrl.zip	Edgar Link	pending
dalrada_ex3101.htm	Edgar Link	pending
dalrada_ex3102.htm	Edgar Link	pending
dalrada_ex3201.htm	Edgar Link	pending
dalrada_ex3202.htm	Edgar Link	pending
dalrada_i10q-033123.htm	Edgar Link	pending
dfco-20230331.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
dfco-20230331_def.xml	Edgar Link	unprocessable
dfco-20230331_lab.xml	Edgar Link	unprocessable
dfco-20230331_pre.xml	Edgar Link	unprocessable
dalrada_i10q-033123_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFCO
DALRADA FINANCIAL CORP Stock $dfco

2023 Q2 Form 10-Q Financial Statement

#000168316823003389 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO DALRADA FINANCIAL CORP Stock $dfco

2023 Q2 Form 10-Q Financial Statement

#000168316823003389 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFCO
DALRADA FINANCIAL CORP Stock $dfco